Atai Life Sciences AG (NASDAQ:ATAI) and IntelGenx Technologies Corp. have completed transactions related to a non-brokered offering of units. The transactions include amendments to a loan agreement and a subscription agreement, providing Atai with the ability to convert the principal and accrued interest into IntelGenx's common stock and the right to purchase additional units. Following the transactions, Atai would beneficially own or control approximately 63.4% of the issued and outstanding shares of IntelGenx.